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analysis of an 84 genes panel is
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 Twenty-two BRCA-negative patients
with familial breast cancer have been
analyzed.
 Two pathogenic mutations and 8
potentially pathogenic variants were
identiﬁed.
 Extended gene proﬁling better de-
ﬁnes the predisposition risk for
breast cancer.
 The diagnostic sensitivity of familial
breast cancer testing is improved.a r t i c l e i n f o
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By analyzing multiple gene panels, next-generation sequencing is more effective than conventional
procedures in identifying disease-related mutations that are useful for clinical decision-making. Here, we
aimed to test the efﬁcacy of an 84 genes customized-panel in BRCA1 and BRCA2 mutation-negative
patients. Twenty-four patients were enrolled in this study. DNA libraries were prepared using a pico-
droplet PCR-based approach and sequenced with the MiSeq System. Highly putative pathogenic muta-
tions were identiﬁed in genes other than the commonly tested BRCA1/2: 2 pathogenic mutations one in
TP53 and one in MUTYH; 2 missense variants in MSH6 and ATM, respectively; 2 frameshift variants in
KLLN, and ATAD2, respectively; an intronic variant in ANPEP, and 3 not functionally known variants (a
frameshift variant in ATM a nonsense variant in ATM and a missense variant in NFE2L2). Our results show
that this molecular screening will increase diagnostic sensitivity leading to a better risk assessment inzate, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche e Ed. 19, Via Sergio Pansini 5, 80131, Naples,
zate, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche e Ed. 19, Via Sergio Pansini 5, 80131, Naples,
dargenio@ceinge.unina.it (V. D'Argenio).
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Picodroplet PCRbreast cancer patients and their families. This strategy could also reveal genes that have a higher
penetrance for breast and ovarian cancers by matching gene mutation with familial and clinical data,
thereby increasing information about hereditary breast and ovarian cancer genetics and improving
cancer prevention measures or therapeutic approaches.
© 2018 Published by Elsevier B.V.1. Introduction
Recent advances in next-generation sequencing (NGS) tech-
nology enabled the use of multiple gene panel tests to identify
disease-related mutations [1]. These strategies, by allowing the
simultaneous analysis of many genes of interest in several patients,
can improve molecular diagnosis because they increase diagnostic
accuracy and sensitivity, besides reducing analytical time and costs.
Consequently, NGS-based gene panel analyses are now frequently
used for the molecular diagnosis of several diseases [2e5]. Hered-
itary breast and ovarian cancer (HBOC) accounts for about 15% of all
breast cancers (BCs), and is thus one of the most common heredi-
tary cancer syndromes [6]. It is associated with an increased life-
time risk of multiple cancers, and often occurs at an earlier agewith
respect to the general population. Therefore, it is important to
identify at-risk subjects, i.e., carriers of cancer-predisposing
germline mutations, in order to offer patients and their families
appropriate cancer surveillance screening and prophylactic thera-
peutic or surgical options [6e9].
It is generally agreed that HBOC is mainly associated to germline
mutations in the tumor suppressor genes BRCA1 and BRCA2 [6,10].
Women with heterozygous mutations in the BRCA1 or BRCA2 genes
have a lifetime risk of developing breast cancer of up to 80% and 60%
respectively, and a cumulative risk of developing ovarian cancer of
up to 60% [6,7]. Therefore, BRCA gene testing is currently offered
worldwide to identify at-risk women, namely, those with a personal
and/or familial history that fulﬁlls the National Comprehensive
Cancer Network guidelines for HBOC testing (NCCN) [11]. However,
only a small proportion (25%) of such at-risk subjects is found to
carry a deleterious mutation of the BRCA genes, which suggests that
other genes may be involved in the development of HBOC [12,13].
In this scenario, NGS-based gene panels that simultaneously
analyze diverse breast cancer-related genes are recently being used
for inherited cancer risk identiﬁcation and deﬁnition [14e17].
However, their use in the clinical setting is debatable because the
number of causative mutations in genes other than the BRCA genes
has been reported to be lower than expected [18,19]. Conversely,
the number of variants with difﬁcult-to-interpret clinical value is
increasing, which suggests that caution be exercised regarding the
application of these tests in routine molecular diagnostics [18,19].
Here, we report the analysis of a customized 84-gene NGS-based
panel designed to analyze the deﬁnition of inherited risk of breast
cancer. By increasing the diagnostic sensitivity of this risk by mo-
lecular testing, our strategy supports the use of a multistep diag-
nostic approach to improve the clinical management of patients
and their families and ameliorate cancer prevention and surveil-
lance programs.2. Material and methods
2.1. Selection of patients and preparation of DNA samples
Twenty-four patients (21 women with BC, 1 man with BC, and 2
unaffected women with a positive family history) attending the
Senology Department of the “Istituto Nazionale dei Tumori -Fondazione G. Pascale” of Naples, Italy, and who did not have a
BRCA1/2 mutation at conventional screening except 2 (see below)
were enrolled in this study (Table 1). Pre-test genetic counseling
was carried out to evaluate each patient's familial cancer history
considering not only breast and ovarian cancers but also other
types of cancer. Although all 24 patients had at least one breast
cancer case in their family, they represent a heterogeneous group
differing in terms of onset time (early versus late), breast cancer
features, and/or a variety of cancers of a different nature, somewith
a high mortality rate even in young patients. Therefore, we postu-
lated that a multiple gene panel could be used to investigate the
predisposition risk of other inherited cancer genes beyond the two
classical breast cancer genes conventionally used. Clinical data,
including personal and family history, were collected and a three-
generation family pedigree was constructed for each subject
showing the number and the type of cancers present in each family
(Table 1 and Figs. 1e3). Only 2 women with breast cancer were
found to carry a mutation in the BRCA2 gene and served also as
positive controls to verify our analytical procedure [20]. All patients
gave their written informed consent to the study that was carried
out according to the tenets of the Helsinki Declaration and
approved by the Istituto Nazionale Tumori - Fondazione G. Pascale
Ethics Committee (protocol number 3 of 03/25/2009).
Genomic DNA was isolated from peripheral blood using the
MasterPure™ Complete DNA Puriﬁcation Kit (Epicentre Madison,
WI, USA) according to the manufacturer's instructions. DNA quan-
tity was evaluated using the NanoDrop 2000c Spectrophotometer
(Thermo Fisher Scientiﬁc, Waltham, MA, USA), while DNA quality
was assessed by 0.8% agarose gel electrophoresis.
2.2. Gene panel selection
We designed a panel of 84 genes constituted by BRCA1 and
BRCA2, and other genes reported to be associated with breast and/
or ovarian cancer [12e19]. For each gene we included the coding
regions, 100 bp in each of the intronic boundaries, the promoter
and the 3’ UTR for a total target size of about 1Mb.
2.3. Custom-enriched library preparation and next generation
sequencing
All samples were analyzed according to the ﬂowchart reported in
Fig. S1 in Supplementary Material and Methods. As an alternative to
other methodologies for libraries preparation used in previous ex-
perimentations, including shotgun libraries, amplicons or probes-
based approaches [1,10,20,21], we used herein a different strategy.
In fact, the targeted enrichment of our customized panel was carried
out using the RainDance ThunderStorm System (RainDance Tech-
nologies, Billerica, MA, USA), which is a microﬂuidic device that
generates millions of unique picodroplet PCR reactions for high
throughput multiplex ampliﬁcation [1]. The miniaturized system
that also includes a liquid handler reduces both hands-on time and
operator-dependent variability. Moreover, when working with GC-
rich regions, repetitive regions or pseudogenes, the separation of
individual amplicons into individual droplet micro-reactors
Table 1
Clinical features of patients enrolled in the study. All patients belonged to families in which at least one case of breast cancer had been reported.
ID Sex Age Under/Over
40 at onset
Proband
Disease Status
BRCA genes
Mutation Status
Menarche
Age
Pregnancies Other Risk Factors Familial Cancer (case number)
P1 F 46 Over Breast cancer WT N.R. N.R. N.R. Breast (1)
P2 F 41 Under Breast cancer WT N.R. 1 Smoke Breast (1), ovarian (1)
P3 F 49 Over Breast cancer WT 14 1 No Breast (3), intestine (1), lymphoma (1), lung (2)
P4 F 44 e Healthy WT 11 2 þ 1
Abortion
No Throat (1), breast (1), prostate (2), bone (4), lung
(1)
P5 F 71 Over Breast cancer WT 12 1 þ 1
Abortion
Smoke Brain (1), breast (1)
P6 M 66 Over Breast cancer WT e e No Breast (1)
P7 F 55 Over LABC WT 11 4 Smoke Breast (3)
P8 F 49 Under Breast cancer WT 12 1 þ 2
Abortion
No Breast (6), prostate (1)
P9 F 38 Under Breast cancer WT 11 3 No Uterus (1), breast (2), bone (1), pancreas (1), throat
(1), lung (1)
P10 F 37 Under Breast cancer WT 14 0 Oral Contraceptives,
Smoke
Melanoma (1), intestine (1), leukemia (1), bladder
(1), breast (4)
P11 F 72 Over Breast cancer WT 12 2 No Intestine (2), lung (1), liver (1), breast (3)
P12 F 57 e Healthy WT 15 2 Oral Contraceptives,
Smoke
Colon (1), breast (3), lung (5), liver (2), stomach (4),
bladder (1), pancreas (1)
P13 F 43 Under Breast cancer WT 12 1 No Breast (3), uterus (1), lung (1), prostate (1)
P14 F 51 Under Breast cancer BRCA2 13 3 Oral Contraceptives,
Smoke
Breast (3), uterus (1)
P15 F 43 Under Breast cancer BRCA2 12 3 þ 1
Abortion
Oral Contraceptives,
Smoke
Breast (3), uterus (1)
P16 F 52 Over Breast cancer WT 11 0 No Throat (1), breast (1)
P17 F 64 Over Breast cancer WT 13 2 Smoke Breast (2), brain (1)
P18 F 64 Over Breast cancer WT 13 2 No Uterus (1), prostate (1), breast (1), kidney (1)
P19 F 39 Under Breast cancer WT 13 2 Oral Contraceptives,
Smoke
Liver (1), breast (2)
P20 F 54 Over Breast cancer WT N.R. 0 Smoke, Ovarian
Stimulation
Throat (1), breast (1)
P21 F 54 Over Breast cancer WT 12 2 þ 1
Abortion
No Lung (2), breast (2), kidney (2), uterus (1)
P22 F 80 Over Breast cancer WT 14 5 þ 1
Abortion
Smoke Breast (4)
P23 F 42 Under Breast cancer WT 13 0 Ovarian Stimulation, Oral
Contraceptives
Breast (3), pancreas (2), lung (1), brain (1)
P24 F 48 Over Breast cancer WT 11 2 þ 2
Abortion
Oral Contraceptives,
Smoke
Breast (2), prostate (2), leukemia (1), lung (2)
P, Patient; F, Female; M, Male; WT, Wild Type; N.R., not reported; LABC, Local Advanced Breast Cancer.
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complex regions, thereby ensuring great coverage uniformity, which
is a prerequisite for any clinical application of NGS. All these features
are prerequisites for the routine analysis of multiple genes in a high
number of patients simultaneously. Consequently, given these im-
provements, we used droplet PCR together with an NGS system as a
more reliable method for the enrichment of NGS libraries, and vali-
dated this approach in a pilot study group.
Eight mg of genomic DNA/sample were fragmented (average
length¼ 3000 bp) using the M220 Focused-ultrasonicator Covaris
(Covaris, Inc., Woburn, MA, USA). Next, 1.5 mg of sheared DNA/
sample were used to generate the ThunderStorm custom emulsion
for the ampliﬁcation of the target genes (amplicon
length¼ 300e500 bp). After ampliﬁcation, the emulsions were
broken, and the enriched libraries were further processed to
amplify the targets and attach personal indices adaptors. Enriched
libraries were quality-assessed on a DNA 1000 LabChip (Agilent
Technologies, Santa Clara, CA, USA). Twelve libraries were pooled
for each sequencing run. Sequencing reactions were performed
with the Illumina MiSeq System (PE 300x2) (Illumina Inc., San
Diego, CA, USA). Causative or potentially interesting variants were
conﬁrmed by Sanger sequencing.2.4. Bioinformatics
Bioinformatic analyses consisted of 6 steps as shown in Fig. S2 inSupplementary Material and Methods. Raw fastq ﬁles were ﬁltered
after quality checking with the NGS QC Toolkit v2.3.3 to remove
primers and trim low quality ends of reads (quality score, QS< 20)
[22]. Reads were aligned against the hg38 genome assembly
(GenBank:GCA_000001405.15) using the BWA software v0.7.12,
mem algorithm [23]. Post-alignment processing was performed
using: i) SAMtools v1.2 for sorting, indexing and merging bam ﬁles;
(ii) Picard tools v1.129 (http://picard.sourceforge.net) to add read
groups; (iii) GATK v3.3 for insertions/deletions (indels) realignment
and base QS recalibration [24,25]. Indels were realigned around
known indels of the 1000 Genomes phase 1, after conversion of
genome coordinates from hg19 (GenBank: GCA_000001405.1) to
hg38 assembly, using CrossMap software v0.1.6 [26,27]. dbSNP
variants (release 142, http://www.ncbi.nlm.nih.gov/SNP/) were
used as reference for base QS recalibration. Variant calling and
ﬁltering were performed using the GATK HaplotypeCaller v3.3 in
GVCF mode and SAMtools mpileup (see online supplementary
Methods) [24,25]. Lastly, variant annotation and prioritization
were performed using SnpEff v.4.1b and dbNSFP v3.0 beta1 tools
(see Supplementary Material and Methods) [28e30].3. Results
3.1. NGS data analysis
We obtained an average of high quality reads of 77%
Fig. 1. Pedigree of P9 and P17. (A) P9, now 39 years old, was diagnosed with bilateral breast cancer at the age of 31 years, and with a primitive lung cancer at the age of 38. The
patient's mother died from cancer, and during her life she was affected by uterine sarcoma, pancreatic cancer and lung cancer. One aunt died from breast cancer at the age of 30
years and an uncle died from unspeciﬁed cancer (both in the maternal arm). (B) P9 was negative for BRCA mutations but we identiﬁed a known pathogenic variant (c.734G>A,
p.Gly245Asp [(rs121912656]) in the TP53 gene, which was conﬁrmed by Sanger sequencing. (C) P17 was diagnosed with breast cancer she was over the age of 40 years. Two sisters
died from breast and brain cancer, respectively. The patient's twin sister also developed breast cancer. (D) In this patient we found the pathogenic variant c.1145G> A, p.Gly382Asp
(rs36053993) in the MUTYH gene, as shown in the Sanger electropherogram.
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Fig. 2. Pedigrees of patients carrying at least one prioritized variant. Pedigrees of P18, P23 and P8 (AeC). The gene and their variants are reported on the top of each panel. The
arrows indicate the proband from each family.
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Results). The alignment showed a very high percentage of mapped
reads in each sample and a few unmapped reads (average 5.0%).
The average mapping quality ranged from 47.8 to 55.2, which
conﬁrms high alignment efﬁciency. Uniquely mapped reads rep-
resented the largest fraction of the total amount of reads (from 91%
to 96%). Fixing a threshold of minimum base quality score¼ 30,
more than 90% of selected regions were almost entirely covered
(>80% of their total exon length) and only 6 regions out of 2316
exons were not covered at all. The mean sample coverage ranged
from 24.00 to 286.76 (Fig. S3A and Table S1 in Supplementary Re-
sults). To call only highly reliable variants, we considered a depth of
coverage 10 acceptable. The percentage of covered target sites,
meant as single bases, was variable within samples at a coverage
depth 10 and 100 (Fig. S3B in Supplementary Results). One
sample (patient 4) that had a very low coverage depth was not
considered in the subsequent analysis.
Overall, in all the 24 samples we found 2324 single nucleotide
variants and 752 indels after variant ﬁltration with a minimum
variant depth of 10 (Table S3 in Supplementary Results). The dis-
tribution of single nucleotide variants and indels within genomic
regions was homogeneous among variants detected by the 3
methods (SAMtools, GATK VQSR and GATK HF) (Fig. S4A and B in
Supplementary Results). About 50% of single nucleotide variants
were missense mutations and only 2 STOP gain mutations were
observed (GATK and VQSR), one of which was conﬁrmed by both
SAMtools and GATK HF (Fig. S4C in Supplementary Results). Eleven
frameshifts/indels were identiﬁed by GATK HF, but only 4 weredetected also by another method, consequently the remaining
mutations were not considered reliable (Fig. S4D in Supplementary
Results). See also supplementary information for further details.
3.2. Reliability of variant calling
The reliability of the targeted enrichment method described
herein was assessed by evaluating its capability to detect gene
sequence variants in the BRCA1 and BRCA2 genes. In fact, we had
previously analyzed the 24 patients enrolled in this study using an
NGS-based protocol to assess their BRCA mutational status [20]. In
particular, in the BRCA1 gene, the Thunderstorm System coupled
with the above-mentioned bioinformatic strategy, identiﬁed 86
variants detected also by the ﬁrst screening analysis (88%),1 variant
was identiﬁed only with the JSI Sequence Pilot software, while 11
were detected only by Thunderstorm but not conﬁrmed by Sanger
sequencing. Similarly, we found 110 variants in the BRCA2 gene that
were detected also by the ﬁrst screening analysis (87.4%), 5 variants
detected only with the JSI Sequence Pilot software, and 11 detected
only by Thunderstorm but not conﬁrmed by Sanger sequencing.
Therefore, based on these data, the sensitivity of our procedurewas
96.6% and its speciﬁcity >99.9%.
3.3. Mutation identiﬁcation in high risk BC patients
The variant annotation and prioritization strategy revealed a
small number of variants of potential interest as cancer-
predisposing mutations in our patients. In fact, we analyzed 11
Fig. 3. Pedigrees of patients carrying at least one prioritized variant. Pedigrees of P5, P2 and P11 (AeC). The gene and their variants are reported on the top of each panel. The
arrows indicate the proband from each family.
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sequencing and found that 3 of them are classiﬁed as pathogenic in
the ClinVar Database (https://www.ncbi.nlm.nih.gov/clinvar/): 1 is
the BRCA2mutation already identiﬁed in the ﬁrst level analysis in 2
patients (Positive Controls in this study); the remaining 2 occurr
one in TP53 and one inMUTYH. The remaining 8 prioritized variants
consist of 1 intronic variant, 3 frameshifts, 1 nonsense and 3
missense variants. All prioritized variants were conﬁrmed by
Sanger sequencing and are reported in Table 2.
In Patient 9 (P9) we identiﬁed a known pathogenic variant
(rs121912656) in the TP53 gene, namely c.734G>A (p.Gly245Asp)
that maps on exon 7/11. TP53 encodes the tumor suppressor gene
p53. This variant alters p53 DNA binding site, characterized by 8
conserved residues. P9 was found to be wild-type in the ﬁrst level
analysis of BRCA1/2, but the many different types of cancers within
her family (breast, uterus, throat, bone, pancreas and lung) and the
young age of BC onset strongly suggested a hereditary component.
During follow-up, Patient 9 was diagnosed with a new primitive
lung cancer (Fig. 1A and B). Therefore, this patient's personal and
familial history is compatible with a pathogenic mutation in the
TP53 gene, given the absence of other major risk factors (i.e. smoke,
oral contraceptives, ovarian stimulation).
In P17 we found a pathogenic variant in the MUTYH gene
(rs36053993). MUTYH encodes an adenine DNA glycosylase
involved in oxidative DNA damage repair. The variant is located oncDNA position c.1145G >A (p.Gly382Asp) in exon 13/16. At protein
level the variant mapped on Nudix hydrolase domain. P17 was
wild-type at BRCA1/2 screening analysis. The family history was
positive principally for breast and brain cancers (Fig. 1C and D).
Patient 18 was found to carry 2 prioritized variants in the ATM
and KLLN genes. The positions on cDNA are c.7235A>G
(p.Asn2412Ser) and c.339_340delAG (p.Tyr113fs), respectively. The
ATM variant is on exon 49/63 and despite the ClinVar annotation of
uncertain signiﬁcance (rs786203311), it has been associated to
hereditary cancer-predisposing syndrome. At protein level, this
variant results in an alteration of the FAT (FRAP, ATM and TRRAP)
domain. The KLLN gene encodes Killin, a 20 kDa nuclear protein
that is necessary for p53-induced apoptosis. The KLLN variant is a
frameshift variant (rs749052307). Although P18 was diagnosed
with BC over the age of 40 years old, she was wild-type for BRCA1/
2 at a screening analysis. She was enrolled in this study due to a
cluster of tumors in the family (kidney, breast, prostate and uterus).
During follow-up, this patient had 2 new primitive cancers: colon
cancer and triple negative breast cancer (Fig. 2A).
Patient 23 has 2 previously unreported prioritized variants in
ATM and NFE2L2. In ATM there is a stop variant in cDNA position
c.6415G> T (p.Glu2139X - rs1339238483) in exon 44/63. At protein
level the stop is in the FAT domain. In the NFE2L2 genewe validated
c.761T> A (p.Phe254Tyr) in exon 5/5. P23 resulted wild-type for
BRCA1/2 at screening analysis. This patient was enrolled in the
Table 2
Variants prioritized through the bioinformatic analysis and validated by the Sanger method.
Gene Patient HGVS cDNA HGVS Protein Reference SNP ID
number
ClinVar
Status
Number of
Pathogenicpredictions
Conserved
Site
gnomAD Browser
Dataa
ExAC
Datab
DANN
Scorec
TP53 P9 c.734G >A p.Gly245Asp rs121912656 Pathogenic 7/9 N/A 0.000004061 (1/
246,236)
1/
121,378
0.9977
BRCA2 P14 c.5796_5797delTA p.His1932Glnfs rs80359537 Pathogenic e N/A e 1/
121,378
e
BRCA2 P15 c.5796_5797delTA p.His1932Glnfs rs80359537 Pathogenic e N/A e 1/
121,378
e
MUTYH P17 c.1145G >A p.Gly382Asp rs36053993 Pathogenic 8/9 N/A 0.002958 (1/338) 1/357 0.9985
ATM P18 c.7235A >G p.Asn2412Ser rs786203311 UCV 4/9 Highly
conserved
e e 0.9889
KLLN P18 c.339_340delAG p.Tyr113fs rs749052307 NA e N/A 0.001778 (1/703) e e
ATAD2 P2 c.804_806delTGA p.Asp269del rs539981908 NA e N/A 0.001712 (1/584) 1/
116,788
e
MSH6 P8 c.2633T > C p.Val878Ala rs2020912 Benign 2/9 N/A 0.005119 (1/195) 1/189 0.7259
ANPEP P11 c.2751þ2dupT e rs751522046 NA e N/A 0.0001056 (1/9469) e e
NFE2L2 P23 c.761T >A p.Phe254Tyr Unreported e 3/9 Highly
conserved
e e 0.9886
ATM P23 c.6415G > T p.Glu2139X rs1339238483 NA 2/9 Highly
conserved
0.000004091 (1/
244,414)
e 0.9968
ATM P5 c.2192dupA p.Tyr731fs rs1478081526 NA e N/A 0.000004065 (1/
246,020)
e e
HGVS, Human Genome Variation Society (http://www.hgvs.org).
ClinVar, Clinical Variation database (https://www.ncbi.nlm.nih.gov/clinvar/).
NA, not available, N/A, not applicable.
a gnomAD Browser Data: The data set provided spans 123,136 exome sequences and 15,496 whole-genome sequences from unrelated individuals sequenced as part of
various disease-speciﬁc and population genetic studies.
b ExAC Data: The data set provided on spans 60,706 unrelated individuals sequenced as part of various disease-speciﬁc and population genetic studies.
c DANN Score: DANN is a pathogenicity scoring methodology developed at the University of California, Irvine. It is based on deep neural networks. The value range is 0e1,
with 1 given to the variants predicted to be the most damaging [40].
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cluster of tumors in the family (breast, pancreas, lung and brain)
(Fig. 2B).
In P8 we prioritized and validated a variant in the MSH6 gene.
Despite 6 cases of BC and 1 of prostate cancer in the family, P8 was
wild-type at BRCA1/2 screening (Fig. 2C). The MSH6 variant is in
cDNA position c.2633T> C (p.Val878Ala) in exon 4/10, and is clas-
siﬁed “benign” in the ClinVar Database (rs2020912). In P5 we
validated a hitherto unknown frameshift variant in the ATM gene.
The variant is in cDNA position c.2192dupA (p.Tyr731fs -
rs1478081526). P5 was wild-type at BRCA1/2 screening and has a
family history of breast and brain cancers (Fig. 3A). In P2 we vali-
dated a known variant (rs539981908) in the ATAD2 gene classiﬁed
as “NA” (not available) for clinical signiﬁcance (Fig. 3B). This variant,
namely c.804_806delTGA (p.Asp269del), causes the in-frame
deletion of one amino acidic residue. Finally, P11 had an intronic
variant in the ANPEP gene (Fig. 3C). This variant, c.2751þ2dupT,
affects the canonic donor splice site in intron 20 and has been
predicted by Human splicing ﬁnder (http://www.umd.be/HSF3/) to
affect the splicing through the loss of the wild-type donor site and
the potential activation of a new cryptic site.
4. Discussion
The molecular analysis reported herein conﬁrmed the patho-
genic mutations in BRCA2, used as positive controls in 2 patients,
and the absence of BRCA1 and BRCA2 pathogenic mutations in the
other 21 patients. The reliability of this new strategy was conﬁrmed
by comparing all the polymorphisms and variants of unknown
signiﬁcance (VUS) identiﬁed in BRCA1 and BRCA2 with those pre-
viously detected in these genes. Using the bioinformatics pipeline
followed by Sanger sequencing validation, we prioritized candidate
cancer-predisposing variants in the other analyzed genes. The re-
sults showed that the two BRCA2-mutated patients had no muta-
tions in the other genes, while the other 21 patients had 10prioritized variants, of which 2 pathogenic mutations, 6 VUS or
variants with no functionally known signiﬁcance, 1 benign and 1
novel variant (Table 2). These variants are distributed differently
among the patients and among the genes. In fact, 8/21 patients
carry at least one prioritized variant, and just 8/82 genes, not
including BRCA1 and BRCA2, present prioritized variants. In
particular, as shown in Table 2, we found three different variants in
ATM, and one variant in each of the following genes TP53, MUTHY,
KLLN, ATAD2, MSH6, ANPEP and NFE2L2.
We detected 2 pathogenetic mutations in two BRCA-negative
patients (Patient 9 and Patient 17). One mutation (c.734G> A
[p.Gly245Asp]) occurred in the TP53 gene. This ﬁnding supports
NCCN guidelines [11] that recommend TP53 testing in BRCA-nega-
tive individuals with BC diagnosed before the age of 35 years.
Germline mutations in TP53 have been associated to the rare
cancer-predisposing syndrome, Li-Fraumeni [31], which features a
wide spectrum of cancers, usually with early onset, also during
childhood [32]. The personal and familial history of Patient 9 is
compatible with Li-Fraumen-related phenotypes. Thus, our multi-
gene panel testing not only revealed a germline cancer-
predisposing mutation in the patient, but also a risk of cancer in
the members of this family, who can consequently now be offered
appropriate cancer surveillance. The other pathogenic mutation
identiﬁed in Patient 17 was c.1145G> A (p.Gly382Asp) in the
MUTYH gene. MUTYH encodes a protein involved in DNA repair,
whose mutations are usually associated to colorectal cancers, and,
as shown bymultiple gene panel testing for cancer risk assessment,
also to breast cancer [33]. In detail, it has been recently estimated
that MUTYH monoallelic mutation carriers have an 11% cumulative
risk of BC, which conﬁrms that this gene should be included in
hereditary cancer risk assessment [34].
Among the other prioritized variants, some could increase the
risk of cancer. In fact, we found a nonsense variant in ATM
(c.6415G> T, p.Glu2139X), an intronic variant in the canonical
splicing site of ANPEP (c.2751þ2dupT), and 2 frameshift variants,
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(c.2192dupA, p.Tyr731fs). Of the other three, two are likely patho-
genetic since one is a deletion and one is amissensemutation in the
NFE2L2 gene. Notably, the overall frequency of germline mutations
in DNA damage repair genes other than the BRCA genes in our
population screened in a third level center was 28.5%, and ATMwas
themost frequently affected gene (33.3%). Although NGS sensitivity
supersedes that of Sanger sequencing, we used Sanger as a second
independent method to verify the speciﬁc variants of potential
interest that we identiﬁed by NGS, and found they were all
conﬁrmed based on the extent of coverage and the quality of the
reads (Q-score 30).
NGS-based screening of a large panel of genes increases the
number of novel variants and variants of unknown clinical signif-
icance; however, in a research setting, it's important to increase the
number of biological variants that may successively be tested
in vitro and in vivo to assess the clinical importance. Notably, the
greater the routine application of gene panel testing, the greater the
epidemiological data on the role of speciﬁc genes and/or mutations,
which in turn will prompt functional studies to clarify their role as
tumor-predisposing factors. Therefore, although not regulated by
validated guidelines, the presence of a germline pathogenic (or
possibly pathogenic) variant in a patient with a personal and/or
family history alerts clinicians to the need for a patient monitoring
program, also in view of treatment strategies.
The method we used is only one of the possible strategies that
can be used to enrich multiple target genes that will be simulta-
neously sequenced by NGS. The aim of our study was to test this
approach since it is based on a picodroplet PCR strategy that en-
sures a high speciﬁcity of PCR reactions and an enhanced capa-
bility of multiplexing (up to 20,000 different amplicons/sample),
since the amplicons are physically separated within the droplets
(that act as individual micro-reactors). As mentioned above,
operator time and operator-dependent variability is greatly
reduced thanks to the miniaturized microﬂuidic device and the
liquid handler incorporated in the system. Another advantage of
this system is that, when working with GC-rich regions, repetitive
regions or pseudogenes the separation of individual amplicons
into individual droplet micro-reactors facilitates high coverage
because it reduces the complexity of these regions thereby
ensuring great coverage uniformity [35], which is essential when
NGS is applied in the clinical setting. Therefore, the tested droplet
PCR combined with NGS is an alternative and reliable method
with which to enrich NGS libraries.
Although limited to a small group of patients, our study shows
the efﬁcacy of NGS-based approaches in hereditary cancer risk
assessment in our patients, based on clinical features and family
history, and indicates the need to introduce an enlarged gene panel
test in BRCA-negative HBOC wild type patients [12e19]. Because
molecular tests for the analysis of large genomic regions of interest
are becoming more widely used thanks also to more powerful and
more sensitive NGS platforms, there is a need to standardize these
procedures for clinical applications. The critical point is, of course,
the large amounts of data generated and the difﬁculties related to
the interpretation of identiﬁed variants. The interpretation of var-
iants of unknown signiﬁcance is critical for the management of
patients and is already a challenge for HBOC counseling, especially
in the case of variants that are open to controversial interpretations
[18,19,36,37]. Obviously, this issue will be ampliﬁed, and will
receive much more critical evaluation, consequent to the wide-
spread use of gene panels that include genes whose role in BC onset
is not well established, as in the cases reported herein. Functional
in vitro evaluations combined with molecular analysis and geno-
type/phenotype correlations, within the same family could shed
light on the pathogenetic effects of novel variants [18,19,38,39].5. Conclusions
The identiﬁcation of at-risk subjects in affected families is
crucial for cancer surveillance and prevention programs. Given the
above considerations, multi-gene testing is advisable and should be
included in a multistep diagnostic ﬂowchart for the evaluation of
HBOC risk, after ﬁrst-level evaluation of BRCAmutation status. The
widespread application of this strategy in diagnostic settings will
increase our ability to understand a larger fraction of familial cancer
cases which at the moment is only 25% based on the two main
genes BRCA1/2, and thus globally improve the care of cancer
patients.
In conclusion, here we describe an affordable methodological
strategy with which to identify BC mutations in genes other than
the BRCA genes. Our strategy revealed a BC-predisposing mutation
in patients who were negative at ﬁrst level BRCA testing, thereby
improving the diagnostic sensitivity of this molecular test. Identi-
ﬁcation of predisposing mutations will aid surgical and therapeutic
decision-making, particularly in view of the novel targeted drugs
that are being developed.
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